The state of lipid metabolism in patients with acute coronary syndrome and chronic kidney disease depending on glomerular filtration rate and smoking factor
DOI:
https://doi.org/10.14739/2310-1210.2024.5.305782Keywords:
acute coronary syndrome, chronic kidney disease, smoking, glomerular filtration rate, dyslipidemiaAbstract
Aim. To study the features of lipid metabolism disorders in patients with acute coronary syndrome (ACS), depending on glomerular filtration rate (GFR) and smoking factor.
Materials and methods. The study included 142 ACS patients (mean age – 59.66 ± 0.78 years). All the patients were divided into two groups according to GFR. Group I comprised 57 individuals with GFR <60 ml/min/1.73 m2; Group II – 85 persons with GFR ≥60 ml/min/1.73 m2. Patients of each group were divided into two subgroups based on smoking status: A – smokers (IA, IIA) and B – non-smokers (IB, IIB). The main serum parameters of lipid metabolism were determined: total cholesterol (TC), low-density lipoprotein cholesterol (LDL cholesterol), high-density lipoprotein cholesterol (HDL cholesterol), triglycerides (TG), non-high-density lipoprotein cholesterol (non-HDL cholesterol).
Results. As compared to Group II, Group I have demonstrated significantly higher (by 21–31 %) mean LDL cholesterol (p < 0.01) and non-HDL cholesterol (p < 0.01); higher (by 11–18 %) TC (p < 0.01) and TG (p < 0.05); lower HDL cholesterol (p < 0.05). The results of the subgroup study (based on the smoking status) have shown 22–36 % higher TC, LDL cholesterol, TG, non-HDL cholesterol and 11–16 % lower HDL cholesterol in smokers (IA, IIA) as compared to those in non-smokers (IB, IIB). The study of the smoker subgroups has revealed 13–23 % higher mean TC, LDL cholesterol, and non-HDL cholesterol in Subgroup IA compared to those in Subgroup IIA. The examined patients with lipid profiles different from the reference values were divided into groups. So, up to 18–22 % more individuals with higher LDL cholesterol and lower HDL cholesterol as compared to reference values were in Group I compared to Group II; in the smoker subgroups (IA, IIA), in comparison to non-smoker ones (IB, IIB), there were up to 19–37 % more individuals with higher TC, TG, compared to reference values; in the subgroup of smokers, i.e. in Subgroup IA compared with Subgroup IIA, there were up to 21–24 % more individuals with lower HDL cholesterol and higher non-HDL cholesterol compared with reference values. A correlation analysis has revealed a moderate inverse correlation between TC, LDL cholesterol, non-HDL cholesterol and GFR in Group I and Group II. Moderate and strong inverse correlations between TC, LDL cholesterol, TG, non-HDL cholesterol values and GFR have been found in subgroups of smokers (IA, IIA) and non-smokers (IB, IIB). In addition, in Subgroups IA and IIA, a moderate direct correlation between pro-atherogenic lipid fractions and smoking index has been found.
Conclusions. Patients with GFR <60 ml/min/1.73 m2, compared to those with GFR ≥60 ml/min/1.73 m2, have been revealed with significantly higher levels of pro-atherogenic lipid fractions – LDL cholesterol, non-HDL cholesterol – by 21–31 %, TC, TG – by 11–18 %; and lower levels of HDL cholesterol. Regardless of GFR, in each of the two subgroups of smokers (IA, IIA), compared to non-smokers (IB, IIB), there was a significant increase in the levels of TC, LDL cholesterol, TG, non-HDL cholesterol (by up to 11–36 %) and a decrease in HDL cholesterol. The most obvious pro-atherogenic changes in the lipid spectrum were detected in patients with GFR < 60 ml/min/1.73 m2 and smoking factor (IA).
References
Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399(10332):1347-58. doi: https://doi.org/10.1016/S0140-6736(21)02391-6
Schuett K, Marx N, Lehrke M. The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. Circ Res. 2023;132(8):902-14. doi: https://doi.org/10.1161/CIRCRESAHA.122.321748
Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi: https://doi.org/10.2174/1573403X14666180711124825
Wang Q, Liang C. Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. J Cardiovasc Pharmacol. 2020;76(6):658-70. doi: https://doi.org/10.1097/FJC.0000000000000914
Nakamura M, Ako J, Arai H, Hirayama A, Murakami Y, Nohara A, et al. Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study. J Atheroscler Thromb. 2019;26(6):559-72. doi: https://doi.org/10.5551/jat.45583
Baek J, He C, Afshinnia F, Michailidis G, Pennathur S. Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease. Nat Rev Nephrol. 2022;18(1):38-55. doi: https://doi.org/10.1038/s41581-021-00488-2
Suh SH, Kim SW. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview. Diabetes Metab J. 2023;47(5):612-29. doi: https://doi.org/10.4093/dmj.2023.0067
Liao S, Lin D, Feng Q, Li F, Qi Y, Feng W, et al. Lipid Parameters and the Development of Chronic Kidney Disease: A Prospective Cohort Study in Middle-Aged and Elderly Chinese Individuals. Nutrients. 2022;15(1):112. doi: https://doi.org/10.3390/nu15010112
Xu L, Li D, Song Z, Liu J, Zhou Y, Yang J, et al. The association between monocyte to high-density lipoprotein cholesterol ratio and chronic kidney disease in a Chinese adult population: a cross-sectional study. Ren Fail. 2024;46(1):2331614. doi: https://doi.org/10.1080/0886022X.2024.2331614
Jeong W. Association between dual smoking and dyslipidemia in South Korean adults. PLoS One. 2022;17(7):e0270577. doi: https://doi.org/10.1371/journal.pone.0270577
Moradinazar M, Pasdar Y, Najafi F, Shahsavari S, Shakiba E, Hamzeh B, et al. Association between dyslipidemia and blood lipids concentration with smoking habits in the Kurdish population of Iran. BMC Public Health. 2020;20(1):673. doi: https://doi.org/10.1186/s12889-020-08809-z
Lee S, Kang S, Joo YS, Lee C, Nam KH, Yun HR, et al. Smoking, Smoking Cessation, and Progression of Chronic Kidney Disease: Results From KNOW-CKD Study. Nicotine Tob Res. 2021;23(1):92-8. doi: https://doi.org/10.1093/ntr/ntaa071
Oliveira Coelho F, Andrade L. Smoking and Kidney Disease: Risk Factors, Challenges, and Preventive Strategies. Contrib Nephrol. 2021;199:179-87. doi: https://doi.org/10.1159/000517749
Dhungana SP, Mahato AK, Ghimire R, Shreewastav RK. Prevalence of Dyslipidemia in Patients with Acute Coronary Syndrome Admitted at Tertiary Care Hospital in Nepal: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2020;58(224):204-8. doi: https://doi.org/10.31729/jnma.4765
Saeed D, Reza T, Shahzad MW, Karim Mandokhail A, Bakht D, Qizilbash FH, et al. Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health. Cureus. 2023;15(12):e51362. doi: https://doi.org/10.7759/cureus.51362
Kim SK, Kim HC, Shim JS, Kim DJ. Effects of cigarette smoking on blood lipids in Korean men: Cardiovascular and Metabolic Diseases Etiology Research Center cohort. Korean J Intern Med. 2020;35(2):369-82. doi: https://doi.org/10.3904/kjim.2019.133
Li Z, Zhu G, Chen G, Luo M, Liu X, Chen Z, et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. Lipids Health Dis. 2022;21(1):111. doi: https://doi.org/10.1186/s12944-022-01721-y
Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, et al. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol. 2019;39(10):1938-66. doi: https://doi.org/10.1161/ATVBAHA.119.312705
Lee C, Park JT, Chang TI, Kang EW, Nam KH, Joo YS, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutr Metab Cardiovasc Dis. 2022;32(2):410-9. doi: https://doi.org/10.1016/j.numecd.2021.09.037
Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Oh KH, et al. Serum triglycerides level is independently associated with renal outcomes in patients with non-dialysis chronic kidney disease: Results from KNOW-CKD study. Front Nutr. 2022;9:1037618. doi: https://doi.org/10.3389/fnut.2022.1037618
Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al. Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD. J Am Heart Assoc. 2019;8(6):e011162. doi: https://doi.org/10.1161/JAHA.118.011162
Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, et al. Non-High-Density Lipoprotein Cholesterol and Progression of Chronic Kidney Disease: Results from the KNOW-CKD Study. Nutrients. 2022;14(21):4704. doi: https://doi.org/10.3390/nu14214704
Muga MA, Owili PO, Hsu CY, Chao JC. Association of lifestyle factors with blood lipids and inflammation in adults aged 40 years and above: a population-based cross-sectional study in Taiwan. BMC Public Health. 2019;19(1):1346. doi: https://doi.org/10.1186/s12889-019-7686-0
Nakamura M, Yamamoto Y, Imaoka W, Kuroshima T, Toragai R, Ito Y, et al. Relationships between Smoking Status, Cardiovascular Risk Factors, and Lipoproteins in a Large Japanese Population. J Atheroscler Thromb. 2021;28(9):942-53. doi: https://doi.org/10.5551/jat.56838
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
